(Q40854948)

24 September 2017

title

A survey of the ethical considerations in randomised trials for lung cancer (English)

1 reference

24 September 2017

0 references

1 reference

Zwitter M

1

1 reference

24 September 2017

Tobias JS

series ordinal

2

1 reference

24 September 2017

publication date

1 March 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

19

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

197-210

1 reference

Do doctors know when their patients don't? A survey of doctor-patient communication in lung cancer

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Lobectomy--video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

The effect of fibrin glueing to seal bronchial and alveolar leakages after pulmonary resections and decortications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Neutron vs. photon radiation therapy for inoperable regional non-small cell lung cancer: results of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Morphology and pathology of radiation-induced esophagitis. Double-blind study of naproxen vs placebo for prevention of radiation injury

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Adjuvant treatment of stage I lung cancer with high-dose vitamin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, meth

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Canc

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

CVM versus ACE in the treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer. Petites Cellules Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Communication with the patient in clinical research.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Informed consent in European multicentre randomised clinical trials--are patients really informed?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Of mice but not men. Problems of the randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Is informed consent essential for all chemotherapy studies?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

Informed consent and truth in medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2897%2900099-8

7 January 2021

10.1016/S0169-5002(97)00099-8

Identifiers

DOI

1 reference

24 September 2017

1 reference